A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-08-28
Adverse events
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 88); relationship: not assessed
Grade 2 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 96); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-26 (study day 105); relationship: not assessed
Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 117); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-28 (study day 169); relationship: N
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-07-10 (study day 301); relationship: not assessed
Data queries
No data queries.